Title
PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS
PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)
Phase
Phase 3Lead Sponsor
University of CantabriaStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
SARS-CoV-2 Infection (COVID-19)Intervention/Treatment
Colchicine plus symptomatic treatment (paracetamol) [colchicine (60301), acetaminophen (61759)] Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)Study Participants
70This is a phase 3 clinical trial, randomized, single-center, opened, controlled, to evaluate efficacy and safety of early administration of colchicines in patients older than 60 years, with high risk of pulmonary complications due to coronavirus SARS-CoV2 (COVID-19). An approximately number of 954 subjects meeting all inclusion and none exclusion criteria will be randomized either to receive colchicines or symptomatic treatment with paracetamol during 21 days.
The primary objective of the study is to determine whether short term course of colchicines reduces number of deaths due to COVID-19 and severe complications due to the virus in elderly patients with comorbidities.
The secondary objective is to determine the safety of colchicines in this patient population.
Approximately 954 subjects who meet all inclusion criteria and none exclusion criteria will be randomized either to receive colchicines or symptomatic treatment (2:1 allocation ratio) during 21 days. Follow-up assessments will occur every 48 hours and always at day 10, 21 and 61 following randomization for evaluation of the occurrence of any trial endpoints or other adverse events.
Colchicine plus symptomatic treatment (paracetamol).
Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced. All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice.
Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
Inclusion Criteria: Patients of both sexes who are at least 60 years old. Diagnosis of COVID-19 infection in the last 72 hours and confirmed by PCR Patient in outpatient follow-up (not hospitalized or under consideration) or institutionalized in senior centers/residences The patient must possess at least two of the following high-risk criteria 60 years of age or older AND Any of the following: Diabetes mellitus, high blood pressure, known pulmonary disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, bicytopenia, pancytopenia, or the existence of simultaneous neutrophilia and lymphopenia The patient must be able and willing to comply with the requirements of this study protocol. Exclusion Criteria: Hospitalized patient or under immediate consideration of doing so Patient taking colchicine for other indications Patient with history of allergic reaction or sensitivity to colchicine Patient with inflammatory bowel disease, gastric ulcer, chronic diarrhea or malabsorption Patient with pre-existing progressive neuromuscular disease Patient with kidney damage and estimated glomerular filtrate rate <30 ml/m at 1732 Patient undergoing chemotherapy for cancer, including haematological malignancies. Patients being treated with CYP3A4 and/or glycoprotein inhibitor drugs Immunosuppressive treatment History of cirrhosis, chronic active hepatitis, severe chronic disease defined by GOT or GPT values exceeding 3 times the upper limit of normal. If the investigator considers it, for any reason, to be an inadequate candidate. Patient and/or legal representative will not have signed the informed consent form.
